Corticotropin-releasing effect of hexarelin, a peptidyl GH secretagogue, in normal subjects pretreated with metyrapone or RU-486, a glucocorticoid receptor antagonist, and in patients with Addison's disease

Neuroendocrinology

Volumn 70, Issue 3, 1999, Pages 200-206

  Arvat, Emanuela ^c   Ramunni, Josefina ^c   Maccagno, Barbara ^c   Giordano, Roberta ^c   Broglio, Fabio ^c   Deghenghi, Romano ^a   Boscaro, Marco ^c   Ghigo, Ezio ^b  

^a Ardana   (France)

^b MOLINETTE HOSPITAL   (Italy)

^c NONE

Author keywords

Addison's disease; Adrenal steroids; Clinical neuroendocrinology; Corticotropin; Growth hormone; Metyrapone; RU 486

Indexed keywords

CORTICOTROPIN; DEXAMETHASONE; GROWTH HORMONE; HEXARELIN; HYDROCORTISONE; HYPOTHALAMUS RELEASING FACTOR; METYRAPONE; MIFEPRISTONE;

ADDISON DISEASE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CORTICOTROPIN BLOOD LEVEL; CORTICOTROPIN RELEASE; FEMALE; GROWTH HORMONE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADDISON DISEASE; ADRENOCORTICOTROPIC HORMONE; ADULT; AGED; FEMALE; GROWTH SUBSTANCES; HORMONE ANTAGONISTS; HUMAN GROWTH HORMONE; HUMANS; HYDROCORTISONE; MALE; METYRAPONE; MIDDLE AGED; MIFEPRISTONE; OLIGOPEPTIDES; RECEPTORS, GLUCOCORTICOID;

EID: 0000714816     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000054477     Document Type: Article

References (47)

1. Bowers CY, Veeraragavan K, Sethumadhavan K: Atypical growth hormone-releasing peptides; in Bereu BB, Walker RF (eds): Growth Hormone. II. Basic and Clinical Aspects. New York, Springer, 1993, pp 203-222.
2. Ghigo E, Arvat E, Muccioli G, Camanni F: Growth hormone-releasing peptides. Eur J Endocrinol 1997;136:445-460.
3. Smith RG, Van der Ploeg LXT, Howard AD, Feighner SD, Cheng K, Hickey GJ, Wryatt MJ, Fisher MH, Nargund RP, Patchett AA: Peptidomimetic regulation of growth hormone secretion. Endocr Rev 1997;18:621-645.
4. Deghenghi R, Boutignon F: Luoni M, Grilli R, Guidi M, Locatelli V: Small peptides as potent releasers of growth hormone. J Pediatr Endocrinol Metab 1995;8:311-313.
5. Korbonits M, Grossman AB: Growth hormone-releasing peptide and its analogues. Novel stimuli to growth hormone release. Trends Endocrinol Metab 1995;6:43-49.
6. Ghigo E, Arvat E, Camanni F: Growth hormone secretagogues as corticotrophin-releasing factors. Growth Hormone IGF-I Res 1998;8: 145-148.
7. Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH: Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998;139:552-561.
8. Arvat E, Maccagno B, Ramunni J, Di Vito L, Broglio F, Deghenghi R, Camanni F, Ghigo E: Hexarelin, a synthetic growth hormone-releasing peptide, shows no interaction with corticotropin-releasing hormone and vasopressin on adenocorticotropin and cortisol secretion in humans. Neuroendocrinology 1997;66:432-438.
9. Arvat E, Di Vito L, Maccagno B, Broglio F, Boghen MF, Deghenghi R, Camanni F, Ghigo E: Effects of GHRP-2 and hexarclin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH, and hCRH. Peptides 1997;18:885-891.
10. Ghigo E, Arvat E, Ramunni J, Colao A, Gianotti L, Deghenghi R, Lombardi G, Camanni F: Adrenocorticotropin-and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome. J Clin Endocrinol Metab 1997;82:2439-2444.
11. Korbonits M, Trainer PJ, Besser GM: The effect of an opiate antagonist on the hormonal changes induced by hexarclin. Clin Endocrinol (Oxf) 1995;43:365-371.
12. Orth DN: Corticotropin-releasing hormone in humans. Endocr Rev 1992;13:164-191.
13. Codd EE, Shu AYL, Walker RF: Binding of a growth hormone-releasing hexapeptide to specific hypothalamic and pituitary binding sites. Neuropharmacology 1989;28:1139-1144.
14. 125I p-benzoyl-phenylalanine Hexarelin derivative. Endocrinology 1998;139:432-435.
15. Muccioli G, Ghè C, Ghigo MC, Papotti M, Arvat E, Boghen MF, Nilsson MHL, Deghenghi R, Ong H, Ghigo E: Specific receptors for synthetic GH secretagogues in the human brain and pituitary gland. J Endocrinol 1998; 157:99-106.
16. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, Uamelin M, Ureniuk DJ, Palyhe OC, Anderson J, Paress PS, Diaz C, Chou N, Liu KK, McKee KK, Pong SS, Cheung LY, Elbrecth A, Dashkeviez M, Keavehs R, Rishy M, Siringjhsingji DJS, Dean DC, Melillo DG, Patchett AA, Nergund R, Srillin PR: A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996;273:974-977.
17. Goth MI, Lyons CE, Canny BY, Thorner MO: Pituitary adenylate cyclase acting polypeptide, growth hormone (GH)-releasing peptide and GH-releasing hormone stimulate GH release through distinct pituitary receptors. Endocrinology 1992;130:939-944.
18. Fairhall KM, Mynett A, Robinson ICAF: Central effects of growth hormone-releasing hexapeptide (GHRP-6) on growth hormone release are inhibited by central somatostatin action. J Endocrinol 1995;144:555-560.
19. Dickson SL, Luckman SM: Induction of c-fos messenger ribonucleic acid in neuropeptide Y and growth hormone (GH)-releasing factor neurons in the rat arcuate nucleus following systemic injection of the GH secretagogue, GH-releasing peptide-6. Endocrinology 1997; 138:771-777.
20. Popovic V, Damjanovic S, Micic D, Djurovic M, Dieguez C, Casanueva FF: Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamo-pituitary disconnection: Evidence that GHRP-6 main action is exerted at the hypothalamic level. J Clin Endocrinol Metab 1995;80:942-947.
21. Pombo M, Barreio J, Penalva A, Peino R, Dieguez C, Casanueva FF: Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection. J Clin Endocrinol Metab 1995;80:3180-3184.
22. Loche S, Cambiaso P, Merola B, Colao A, Faedda A, Imbimbo BP, Deghenghi R, Lombardi G, Cappa M: The effect of Hexarelin on growth hormone (GH) secretion in patients with GH deficiency. J Clin Endocrinol Metab 1995;80:2692-2696.
23. Massoud AF, Hindmarsh PC, Brook CGD: Interation of the growth hormone-releasing peptide hexarelin with somatostatin. Clin Endocrinol 1997;47:537-547.
24. Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO: Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab 1990;70:975-982.
25. Arvat E, Gianotti L, Di Vito L, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F, Ghigo E: Modulation of growth hormone-releasing activity of hexarelin in man. Neuroendocrinology 1995;61:51-56.
26. Penalva A, Carballo A, Pombo M, Casanueva FF, Dieguez C: Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man. J Clin Endocrinol Metab 1993;76:168-171.
27. Hickey GJ, Drisko J, Faidley T, Chang C, Anderson L, Nicolich S, McGuire L, Riches E, Krupe D, Feeney W, Friscino R, Cunningham P, Frazier E, Chen H, Leroque P, Smith RG: Mediation by the central nervous system is critical to the in vivo activity of the GH secretagogue L-692,585. J Endocrinol 1996;148:371-380.
28. Schleim KD, Jacks T, Cunningham P, Feeney W, Frazier EG, Niebauer GW, Zhang D, Chen H, Smith RG, Hickey G: Increases in circulating insulin-like growth factor 1 levels by the oral growth hormone secretagogue MK-0677 in the beagle are dependent upon pituitary mediation. Endocrinology 1999;140:1552-1558.
29. Thomas GB, Fairhall KM, Robinson ICAF: Activation of the hypothalamo-pituitary-adrenal axis by the growth hormone (GH) secretagogue, GH-releasing peptide-6. in rats. Endocrinology 1997;138:1585-1591.
30. Arvat E, Maccagno B, Ramunni J, Di Vito L, Gianotti L, Broglio F, Benso A, Deghenghi R, Camanni F, Ghigo E: Effects of dexamethasone and alprazolam, a benzodiazepine, on the stimulatory effect of Hexarelin, a synthetic GHRP, on ACTH, cortisol and GH secretion in humans. Neuroendocrinology 1998;67:310-316.
31. Arvat E, Ramunni J, Giordano R, Maccagno B, Broglio F, Benso A, Deghenghi R, Ghigo E: Effects of the combined administration of Hexarelin, a synthetic peptidyl GH secretagogue, and hCRH on ACTH, cortisol and GH secretion in patients with Cushing's disease. J Endocrinol Invest 1999;22:23-28.
32. Arvat E, Giordano R, Ramunni J, Arnaldi G, Colao A, Deghenghi R, Lombardi G, Mantero F, Camanni F, Ghigo E: Adrenocorticotropin and cortisol hyperresponsiveness to Hexarelin in patients with Cushing's disease bearing a pituitary microadenoma, but not in those with macroadenoma. J Clin Endocrinol Metab 1998;83:4207-4211.
33. Liddle GW, Estep HL, Kendall JW Jr, Williams WC J, Towens AW: Clinical application of a new test of pituitary reserve. J Clin Endocrinol Metab 1959;19:875-894.
34. Bertagna X, Bertagna C, Luton JP, Husson JM, Girard F: The new steroid analog RU-486 inhibits glucocorticoid action in man. J Clin Endocrinol Metab 1984;59:25-28.
35. Baulieu EE: The steroid hormone antagonist RU-486: Mechanism at the cellular level and clinical applications. Endocrinol Metab Clin North Am 1991;20:873-890.
36. Casanueva FF, Burguera B, Alvarez CV, Zugaza JL, Pombo M, Dieguez C: Corticoids as a new stimulus of growth hormone secretion in man. J Pediatr Endocrinol 1992;5:85-90.
37. Smith RG, Cheng K, Schoen WR, Pong SS, Hickey G, Jacks T, Butler B, Chan WW, Chaung LPY, Judith F, Taylor J, Wivratt MJ, Fisher MH: A non-peptidyl GH secretagogue. Science 1993;260:1640-1643.
38. Elias KA, Ingle GS, Burnier JP, Hammonds RG, McDowell RS, Rawson TE, Somers TC, Stanley MS, Cronin MJ: In vitro characterization of four novel classes of growth hormone-releasing peptide. Endocrinology 1995;136: 5694-5699.
39. Shimon I, Yan X, Melmed S: Human fetal pituitary expresses functional growth hormone-releasing peptide receptors. J Clin Endocrinol Metab 1998;83:174-178.
40. De Keyzer Y, Lenne F, Bertagna X: Widespread transcription of the growth hormone-releasing peptide receptor gene in neuroendocrine human tumors. Eur J Endocrinol 1997; 137:715-718.
41. Dorin RJ, Ferries LM; Roberts B, Quails CR, Veldhuis JD, Lisansky EJ: Assessment of stimulated and spontaneous adrenocorticotropin secretory dynamics identifies distinct components of cortisol feedback inhibition in healthy humans. J Clin Endocrinol Metab 1996;81: 3883-3891.
42. Conte-Devolx B, Guillame V, Boudouresque F: Effects of metyrapone infusion on corticotropin-releasing factor and arginine vasopressin secretion into the hypophysial portal blood of conscious, unrestrained rams. Acta Endocrinol 1992;127:435-440.
43. Laue C: Chrousos GP, Loriaux DL, Barnes K, Munson P, Nieman L, Schaison G: The anti-glucocorticoid and antiprogestin steroid RU-486 suppresses the adrenocorticotropin response to ovine corticotropin-releasing hormone in man. J Clin Endocrinol Metab 1988; 66:290-293.
44. Gertz BJ, Scibberas DG, Yogendran L, Christie K, Bador K, Krupa D, Witterich JM, James I: L-692,429, a non-peptide growth hormone (GH) secretagogue reverses glucocorticoid suppression of GH secretion. J Clin Endocrinol Metab 1994;79:745-749.
45. Giustina A, Bussi AR, Deghenghi R, Imbimbo BP, Licini M, Poiesi C, Wehrenberg WB: Comparison of the effects of growth hormone-releasing hormone and hexarelin, a novel growth hormone-releasing peptide-6 analog, on growth hormone secretion in humans with or without glucocorticoid excess. J Endocrinol 1995;146:227-232.
46. Ghigo E, Arvat E, Bellone J, Ramunni J, Camanni F: Neurotransmitter control of growth hormone secretion in humans. J Pediatr Endocrinol 1993;6:263-266.
47. Giustina A, Romanelli G, Bossoni S, Girelli A, Pizzocolo G, Valentini U, Zuccato F: Effects of short-term glucocorticoid deprivation on growth hormone (GH) response to GH-releasing hormone in man. Horm Metab Res 1989; 21:693-694.